| Synonyms: | |
| Status: | Approved (2024) |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 5P60F84FBH |
| InChI Key | YALNUENQHAQXEA-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C24H27N3O4 |
| Molecular Weight | 421.5 |
| AlogP | 4.55 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 3.0 |
| Number of Rotational Bond | 8.0 |
| Polar Surface Area | 90.9 |
| Molecular species | BASE |
| Aromatic Rings | 3.0 |
| Heavy Atoms | 31.0 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class I
|
- | 133 | - | 2-2 | - | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIa
|
- | 512 | - | 1050-1050 | - | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | 44-312 | - | 4-4 | - | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IV
|
- | 287 | - | - | - | |
|
Unclassified protein
|
- | 136 | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Muscular Dystrophy, Duchenne | 3 | D020388 | ClinicalTrials |
| Muscular Dystrophy, Duchenne | 3 | D020388 | ClinicalTrials |
| Muscular Dystrophy, Duchenne | 3 | D020388 | ClinicalTrials |
| Myeloproliferative Disorders | 2 | D009196 | ClinicalTrials |
| Arthritis, Juvenile | 2 | D001171 | ClinicalTrials |
| Multiple Myeloma | 2 | D009101 | ClinicalTrials |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | D015451 | ClinicalTrials |
| Polycythemia Vera | 1 | D011087 | ClinicalTrials |
| Crohn Disease | 1 | D003424 | ClinicalTrials |
| Hodgkin Disease | 1 | D006689 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 497833-27-9 |
| ChEBI | 94187 |
| ChEMBL | CHEMBL1213492 |
| DrugBank | DB12645 |
| EPA CompTox | DTXSID70198049 |
| FDA SRS | 5P60F84FBH |
| Guide to Pharmacology | 7490 |
| PDB | QCM |
| PubChem | 9804992 |
| SureChEMBL | SCHEMBL1555814 |
| ZINC | ZINC000003820616 |